Literature DB >> 9125539

Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.

F Chen1, G M Kuziemko, P Amersdorfer, C Wong, J D Marks, R C Stevens.   

Abstract

The domain organization of the botulinum neurotoxin serotype A was studied by using antibody mapping of 44 monoclonal single-chain variable fragments. The analysis was carried out on (i) the individual domains of botulinum neurotoxin holotoxin (binding, translocation, and catalytic), (ii) botulinum neurotoxin holotoxin, (iii) the botulinum neurotoxin holotoxin in complex with the nontoxic portion, and (iv) botulinum neurotoxin holotoxin and nontoxic portion of the complex recombined in vitro. All 44 antibodies mapped to individual domains of botulinum neurotoxin. Forty of the 44 single-chain variable fragments bound the botulinum neurotoxin holotoxin relative to the isolated domains, suggesting that 4 epitopes are covered when the individual domains are in the holotoxin form. Only 20 of the antibodies showed a positive reaction to the toxin while in complex with the nontoxic portion. All of the covered epitopes were mapped to the binding domain of botulinum neurotoxin, which suggested that the binding domain is in direct contact with the nontoxic portion in the complex. Based on the antibody mapping to the different domains of the botulinum neurotoxin holotoxin and the entire complex, a model of the botulinum neurotoxin complex is proposed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125539      PMCID: PMC175186          DOI: 10.1128/iai.65.5.1626-1630.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Intestinal absorption of botulinum toxins of different molecular sizes in rats.

Authors:  S Sugii; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

2.  Identification of functional and structural amino-acid residues by parsimonious mutagenesis.

Authors:  R Schier; R F Balint; A McCall; G Apell; J W Larrick; J D Marks
Journal:  Gene       Date:  1996-03-09       Impact factor: 3.688

3.  Evaluation of type A botulinal toxin assays that use antitoxin to crystalline toxin.

Authors:  H Sugiyama; I Oishi; B R Dasgupta
Journal:  Appl Microbiol       Date:  1974-02

4.  The role of sulfhydryl groups in the activity of type A botulinum toxin.

Authors:  J Knox; W P Brown; L Spero
Journal:  Biochim Biophys Acta       Date:  1970-08-21

5.  Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A.

Authors:  B R Dasgupta; D A Boroff; E Rothstein
Journal:  Biochem Biophys Res Commun       Date:  1966-03-22       Impact factor: 3.575

Review 6.  Clostridium botulinum neurotoxin.

Authors:  H Sugiyama
Journal:  Microbiol Rev       Date:  1980-09

7.  Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.

Authors:  L L Simpson
Journal:  J Pharmacol Exp Ther       Date:  1980-01       Impact factor: 4.030

8.  Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes.

Authors:  S Sugii; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity.

Authors:  C C Shone; P Hambleton; J Melling
Journal:  Eur J Biochem       Date:  1985-08-15

10.  Purification and amino acid composition of type A botulinum neurotoxin.

Authors:  B R DasGupta; V Sathyamoorthy
Journal:  Toxicon       Date:  1984       Impact factor: 3.033

View more
  25 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

2.  Characterization of toxin complex produced by a unique strain of Clostridium botulinum serotype D 4947.

Authors:  Kimiko Hasegawa; Toshihiro Watanabe; Hiroaki Sato; Yoshimasa Sagane; Shingo Mutoh; Tomonori Suzuki; Akihito Yamano; Hirokazu Kouguchi; Kouichi Takeshi; Arihide Kamaguchi; Yukako Fujinaga; Keiji Oguma; Tohru Ohyama
Journal:  Protein J       Date:  2004-08       Impact factor: 2.371

3.  Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.

Authors:  F Chen; G M Kuziemko; R C Stevens
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.

Authors:  Shenyan Gu; Sophie Rumpel; Jie Zhou; Jasmin Strotmeier; Hans Bigalke; Kay Perry; Charles B Shoemaker; Andreas Rummel; Rongsheng Jin
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

5.  Structural biology. How a neurotoxin survives.

Authors:  Michael Adler
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

6.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 7.  Protein Structure Facilitates High-Resolution Immunological Mapping.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

Review 8.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

Review 9.  Assembly and function of the botulinum neurotoxin progenitor complex.

Authors:  Shenyan Gu; Rongsheng Jin
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.